Welcome to our dedicated page for Quanterix news (Ticker: QTRX), a resource for investors and traders seeking the latest updates and insights on Quanterix stock.
Quanterix Corporation (NASDAQ: QTRX) generates news that spans scientific breakthroughs, clinical research, corporate developments, and financial performance, all centered on its ultra-sensitive Simoa biomarker detection technology and spatial biology capabilities. As a life sciences company active in testing laboratories and professional scientific services, Quanterix regularly reports on studies, collaborations, and product launches that affect disease research and diagnostics.
Investors and researchers following QTRX news will see coverage of peer‑reviewed studies that rely on Simoa assays, such as large population-based analyses of Alzheimer’s Disease Neuropathological Changes using p‑Tau 217, and multiple sclerosis research that combines GFAP and NfL biomarkers for personalized monitoring. These articles illustrate how Quanterix assays and reference databases are applied in real-world clinical and epidemiological settings.
The company also issues updates on new assay launches and platform enhancements, including commercial introductions of p‑Tau 205 and p‑Tau 212 assays for Alzheimer’s research, and developments at the Quanterix Accelerator Laboratory, which supports clinical testing and global clinical trials. News items may highlight regulatory milestones, such as clinical laboratory permits and medical device registrations for specific assay kits in various markets.
From a corporate and capital markets perspective, Quanterix news includes quarterly financial results, non‑GAAP performance metrics, and commentary on integration progress following its acquisition of Akoya Biosciences. Filings and press releases discuss cost synergies, revenue composition across product and service lines, and governance changes such as cooperation agreements with shareholders and Board structure updates.
This QTRX news page brings together these updates so readers can track scientific publications, diagnostic advancements, spatial biology integration, and financial disclosures in one place.
Quanterix Corporation (NASDAQ: QTRX) announced that its Chairman and CEO, Kevin Hrusovsky, will participate in a virtual fireside chat at the Canaccord Genuity 41st Annual Growth Conference on August 12 at 12:00 p.m. ET. He will also conduct virtual meetings with institutional investors. The live webcast will be available on Quanterix's investor relations website, with replays accessible for 90 days. Quanterix focuses on digitizing biomarker analysis through its Simoa technology, enhancing early disease detection and treatment methods across various therapeutic areas.
Quanterix Corporation (NASDAQ: QTRX) announced that Eli Lilly presented new data from the Phase 2 TRAILBLAZER-ALZ study at AAIC 2021, utilizing Quanterix’ Simoa® technology. The data indicate a significant reduction in blood levels of phosphorylated Tau protein after treatment with donanemab, highlighting Simoa’s role in Alzheimer’s research. More than 80 abstracts based on Simoa technology were presented at the event. Quanterix continues to focus on advancing therapies for neurodegenerative diseases, aiming for earlier detection and improved patient outcomes.
Quanterix Corporation (NASDAQ: QTRX) reported significant financial growth for Q2 2021, achieving a GAAP total revenue of $25.4M, up 93% from $13.1M in Q2 2020. Non-GAAP total revenue increased 86% to $24.4M. Product revenue soared by 175% to $18.7M. Gross margins improved, with Q2 GAAP gross margin at 54.7%, up from 39.7% in 2020. The company also made strides in diagnostics for neurodegenerative diseases, enhancing methodologies for disease progression monitoring. Leadership changes included the appointment of Masoud Toloue as President and Michael Doyle as CFO.
Quanterix Corporation (NASDAQ: QTRX) will release its second quarter 2021 financial results on August 5, 2021, after market close. A conference call is scheduled for 4:30 PM ET, hosted by CEO Kevin Hrusovsky, to discuss the results and provide a business update. Investors can join by calling 833-686-9351 (domestic) or 612-979-9890 (international) and using conference ID 2299526. A live webcast of the call will be available at this link.
Quanterix Corporation (NASDAQ: QTRX) announced the appointment of Michael Doyle as the new Chief Financial Officer (CFO) and Treasurer, effective July 12, 2021. Doyle replaces Shawn Stetson, who served in an interim capacity. Doyle brings significant experience as a public company CFO, having previously worked at Forrester Research, where he oversaw a team of 85 and managed multiple acquisitions while growing revenue from $200M to $500M. His appointment is seen as a strategic move to enhance the company’s prospects in advancing precision health through its digital biomarker analysis technology.
Quanterix Corporation (NASDAQ: QTRX) announced significant research utilizing its Simoa® technology to assess the plasma neurofilament light (NfL) biomarker for neurological disorders. Published in Nature Communications, this study involved 2,269 individuals and aims to enhance non-invasive diagnostics in neurodegenerative conditions. Findings confirm plasma NfL's potential in differentiating disorders and establishing age-related cutoffs vital for clinical applications. The research underscores NfL's role in precision health, bolstering Quanterix’s position as a leader in biomarker analysis.
Quanterix Corporation (NASDAQ:QTRX) has announced that its Chairman and CEO, Kevin Hrusovsky, will present virtually at the Goldman Sachs 42nd Annual Global Healthcare Conference on June 10 at 3:50 PM ET. The public can join the webcast via this link, with replays available for 90 days. Additionally, Hrusovsky will appear on The Bio Report podcast on June 3 at 4:00 PM EDT, accessible on various streaming platforms.
Quanterix Corporation (NASDAQ: QTRX) has appointed Masoud Toloue as President, effective June 9, 2021. Toloue brings extensive experience from PerkinElmer, where he significantly grew their diagnostics sector. The company highlighted advancements in diagnostics, particularly in response to COVID-19 and neurological disorders such as Multiple Sclerosis and Alzheimer’s. Toloue's expertise is expected to drive growth as he oversees the diagnostics business and corporate development. Quanterix aims to enhance precision health through innovative digital biomarker technology.
Quanterix Corporation (NASDAQ: QTRX) reported significant financial growth for Q1 2021, with total revenue increasing to $27.2M, up from $15.7M in Q1 2020, driven by a 86% rise in product revenues to $18.2M. The company achieved a gross margin of 60.1%, compared to 43.3% the previous year. Notably, Quanterix received Emergency Use Authorization for its Simoa® SARS-CoV-2 N Protein Antigen Test. The firm raised approximately $270M in a follow-on offering, strengthening its financial position. The demand for neurodegenerative disease assays, particularly for Alzheimer’s, remains robust.
Quanterix Corporation (NASDAQ: QTRX) will release its financial results for Q1 2021 on May 5, 2021, after market close. A conference call hosted by CEO Kevin Hrusovsky will take place at 4:30 p.m. ET to discuss the results and provide a business update. Interested parties can join by phone or through a live webcast available on Quanterix's website. The company specializes in digitizing biomarker analysis, aiming to enhance precision health through early disease detection and improved treatment methods across various therapeutic areas.